408 related articles for article (PubMed ID: 31104135)
21. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
Kishnani PS; Beckemeyer AA; Mendelsohn NJ
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
[TBL] [Abstract][Full Text] [Related]
22. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
[TBL] [Abstract][Full Text] [Related]
23. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.
Schoser B; Bilder DA; Dimmock D; Gupta D; James ES; Prasad S
BMC Neurol; 2017 Nov; 17(1):202. PubMed ID: 29166883
[TBL] [Abstract][Full Text] [Related]
24. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
[TBL] [Abstract][Full Text] [Related]
25. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
Toscano A; Schoser B
J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164
[TBL] [Abstract][Full Text] [Related]
26. [Pompe disease treated with enzyme replacement therapy in pregnancy].
Grosz Z; Várdi KV; Molnár JM
Ideggyogy Sz; 2020 Sep; 73(9-10):339-344. PubMed ID: 33035415
[TBL] [Abstract][Full Text] [Related]
27. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
28. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
[TBL] [Abstract][Full Text] [Related]
29. Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.
Kronn DF; Day-Salvatore D; Hwu WL; Jones SA; Nakamura K; Okuyama T; Swoboda KJ; Kishnani PS;
Pediatrics; 2017 Jul; 140(Suppl 1):S24-S45. PubMed ID: 29162675
[TBL] [Abstract][Full Text] [Related]
30. Body composition and 6 minute walking ability in late-onset pompe disease patients after 9 years of enzyme replacement therapy.
Terzis G; Papadimas G; Krase A; Kontou E; Arnaoutis I; Papadopoulos C
Int J Neurosci; 2022 Jul; 132(7):699-705. PubMed ID: 33045893
[TBL] [Abstract][Full Text] [Related]
31. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
[TBL] [Abstract][Full Text] [Related]
32. Toward deconstructing the phenotype of late-onset Pompe disease.
Schüller A; Wenninger S; Strigl-Pill N; Schoser B
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):80-8. PubMed ID: 22253010
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
34. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
35. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
[TBL] [Abstract][Full Text] [Related]
36. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.
van der Ploeg AT; Kruijshaar ME; Toscano A; Laforêt P; Angelini C; Lachmann RH; Pascual Pascual SI; Roberts M; Rösler K; Stulnig T; van Doorn PA; Van den Bergh PYK; Vissing J; Schoser B;
Eur J Neurol; 2017 Jun; 24(6):768-e31. PubMed ID: 28477382
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
38. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.
Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N
Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498
[TBL] [Abstract][Full Text] [Related]
39. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of Pompe disease in China: a report from the Pompe registry.
Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
